Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 4Unspecified Childhood Solid Tumor, Protocol Specific 2Solid Tumor 2Advanced Solid Tumors 2Wilms Tumor 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Refractory Solid Tumors in Children 1Refractory Solid Tumors 1Recurrence 1Prostatic Neoplasms 1Prostate Cancer Recurrent 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Medulloblastoma 1Malignant Solid Tumors 1

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1asciminib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumors × Sirolimus × Other solid neoplasm × Clear all
NCT05508620 2022-08-23

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1 Unknown
270 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡